Suppliers and packagers for generic pharmaceutical drug: BEPOTASTINE BESILATE

BEPOTASTINE BESILATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	214588	ANDA	Alembic Pharmaceuticals Limited	46708-598-05	1 BOTTLE in 1 CARTON (46708-598-05) / 5 mL in 1 BOTTLE	2023-04-05
Alembic	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	214588	ANDA	Alembic Pharmaceuticals Limited	46708-598-10	1 BOTTLE in 1 CARTON (46708-598-10) / 10 mL in 1 BOTTLE	2023-04-05
Alembic	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	214588	ANDA	Alembic Pharmaceuticals Inc.	62332-598-05	1 BOTTLE in 1 CARTON (62332-598-05) / 5 mL in 1 BOTTLE	2023-04-05
Alembic	BEPOTASTINE BESILATE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	214588	ANDA	Alembic Pharmaceuticals Inc.	62332-598-10	1 BOTTLE in 1 CARTON (62332-598-10) / 10 mL in 1 BOTTLE	2023-04-05

Bepotastine Besilate Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for bepotastine besilate, a second-generation H1-antihistamine. The analysis focuses on key manufacturers of the active pharmaceutical ingredient (API) and critical excipients, patent landscapes, and regulatory considerations impacting supply.

Who Are the Primary Manufacturers of Bepotastine Besilate API?

The production of bepotastine besilate API is concentrated among a limited number of specialized chemical manufacturers. These companies possess the necessary expertise in complex organic synthesis and adhere to stringent Good Manufacturing Practices (GMP) required for pharmaceutical production.

Key API Manufacturers:

• Mylan Laboratories Limited (part of Viatris): Mylan, a significant player in the generics market, is a known manufacturer of bepotastine besilate API. Their facilities are FDA-approved and operate under global regulatory standards.
• Sunrise Remedies Pvt. Ltd.: This Indian pharmaceutical company is a supplier of bepotastine besilate API, catering to both domestic and international markets.
• Neuland Laboratories Ltd.: Neuland is a Hyderabad-based API manufacturer with a strong focus on complex chemistries, including antihistamines. They are a significant supplier in the global generics API market.
• Divi’s Laboratories Limited: Another major Indian API manufacturer, Divi's Laboratories has a broad portfolio and the capacity to produce various complex APIs, potentially including bepotastine besilate.

These manufacturers typically operate under contract manufacturing agreements or supply the API to multiple generic drug formulators. Supply chain reliability is a critical factor, as disruptions can impact the availability of the finished drug product. The quality of the API, confirmed through Certificates of Analysis (CoAs) and regulatory inspections, is paramount.

What Are the Key Excipients Used in Bepotastine Besilate Formulations?

Bepotastine besilate is formulated into oral tablets and ophthalmic solutions. The selection of excipients is critical for drug delivery, stability, and patient compliance.

Common Excipients in Bepotastine Besilate Tablets:

• Diluents/Fillers: These provide bulk to the tablet.
  • Microcrystalline Cellulose (MCC): Widely used for its compressibility and inertness.
  • Lactose Monohydrate: A common disaccharide filler.
• Binders: These hold the tablet ingredients together.
  • Hydroxypropyl Cellulose (HPC): A versatile binder offering good compressibility and disintegration properties.
  • Povidone (PVP): Another effective binder for tablet granulation.
• Disintegrants: These help the tablet break apart in the digestive tract.
  • Croscarmellose Sodium: A superdisintegrant that swells rapidly upon contact with water.
  • Sodium Starch Glycolate: Another commonly used superdisintegrant.
• Lubricants: These prevent sticking to tablet press machinery.
  • Magnesium Stearate: A standard lubricant in tablet manufacturing.
• Glidants: These improve powder flow.
  • Colloidal Silicon Dioxide: Enhances powder flow properties.
• Coating Agents: For film-coated tablets.
  • Hypromellose (HPMC): Used for film coating, improving appearance and ease of swallowing.
  • Titanium Dioxide: A white pigment for coating.

Common Excipients in Bepotastine Besilate Ophthalmic Solutions:

• Buffering Agents: Maintain pH for stability and comfort.
  • Sodium Phosphate Monobasic and Dibasic: Commonly used buffer systems.
  • Citric Acid/Sodium Citrate: Another potential buffer system.
• Tonicity Agents: Adjust osmotic pressure to match that of tears.
  • Sodium Chloride: The most common tonicity agent.
  • Glycerol: Can also be used as a tonicity agent.
• Preservatives: Prevent microbial contamination in multi-dose containers.
  • Benzalkonium Chloride (BAK): A common broad-spectrum preservative in ophthalmic preparations.
  • Edetate Disodium (EDTA): Often used as a chelating agent to enhance preservative efficacy.
• Viscosity Enhancers: Improve residence time on the ocular surface.
  • Hypromellose (HPMC): Can be used to increase viscosity.
  • Carboxymethylcellulose Sodium (CMC-Na).

The supply of these excipients is typically from large, multinational chemical companies and specialized pharmaceutical excipient manufacturers. Reliable sourcing and consistent quality are crucial to ensure the finished drug product meets all specifications.

What Is the Patent Landscape for Bepotastine Besilate?

The patent landscape for bepotastine besilate is primarily characterized by patents covering the compound itself, its synthesis, and specific formulations. As the original patents expire, the focus shifts to process patents and formulation patents, which are critical for generic manufacturers seeking to enter the market.

Key Patent Areas:

• Composition of Matter Patents: The initial patents protecting the bepotastine molecule itself have largely expired in major markets. For instance, the original patent for bepotastine was filed in Japan in 1981 by Kaken Pharmaceutical Co., Ltd. [1].
• Process Patents: These patents cover specific methods of synthesizing bepotastine besilate. Generic manufacturers often develop alternative synthesis routes to circumvent existing process patents or to achieve greater efficiency and cost-effectiveness. These patents can significantly impact market entry.
• Formulation Patents: Patents may cover specific tablet compositions, ophthalmic solution formulations, or drug delivery systems that improve efficacy, reduce side effects, or enhance patient convenience. These can provide a period of market exclusivity for specific branded or generic products.
• Polymorph Patents: Patents protecting specific crystalline forms (polymorphs) of bepotastine besilate can also be relevant, as different polymorphs can exhibit varying stability, solubility, and bioavailability.

Example of Patent Expirations and Generic Entry:

In the United States, the expiry of key patents has paved the way for generic versions of bepotastine besilate tablets. For example, the FDA has approved multiple generic versions of bepotastine besilate tablets 1.5 mg. The availability of generic versions typically leads to a significant reduction in pricing.

Navigating the patent landscape requires detailed analysis of granted patents, pending applications, and potential patent litigation. Freedom-to-operate (FTO) analyses are essential for companies developing generic versions of the drug.

What Are the Regulatory Considerations for Bepotastine Besilate Production and Approval?

Regulatory compliance is fundamental throughout the lifecycle of bepotastine besilate, from API manufacturing to finished product approval and marketing. Key regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

Key Regulatory Aspects:

• Good Manufacturing Practices (GMP): All manufacturing facilities involved in producing bepotastine besilate API and finished drug products must comply with current GMP standards. This includes stringent controls over quality management systems, personnel, facilities and equipment, raw material sourcing, manufacturing processes, and documentation.
  • FDA GMP Regulations: 21 CFR Parts 210 and 211.
  • EMA GMP Guidelines: EudraLex Volume 4.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically file DMFs (in the US) or ASMFs (in Europe) with regulatory agencies. These confidential documents detail the manufacturing process, quality control, and stability of the API. Finished drug product manufacturers reference these filings in their marketing authorization applications.
• Marketing Authorization Applications (MAAs) / New Drug Applications (NDAs) / Abbreviated New Drug Applications (ANDAs): Companies seeking to market bepotastine besilate finished products must submit comprehensive applications to regulatory authorities.
  • NDAs/ANDAs (US): For novel or generic drugs, respectively.
  • MAAs (EU): For marketing authorization in the European Union.
• Bioequivalence Studies: For generic versions of bepotastine besilate, bioequivalence studies are required to demonstrate that the generic product performs comparably to the reference listed drug (RLD) in terms of rate and extent of absorption.
• Stability Testing: Manufacturers must conduct extensive stability testing on both the API and the finished drug product to establish shelf life and recommended storage conditions. This testing follows ICH guidelines (e.g., ICH Q1A(R2)).
• Impurity Profiling: Regulatory authorities require thorough identification and quantification of impurities in the API and finished product. Limits for impurities are set based on safety considerations.
• Pharmacovigilance: Post-market surveillance and reporting of adverse events are mandatory.

Adherence to these regulations ensures the quality, safety, and efficacy of bepotastine besilate products available to patients. Regulatory changes and evolving quality standards require continuous vigilance from manufacturers.

What Are the Market Dynamics and Competitive Landscape?

The market for bepotastine besilate is primarily driven by the demand for prescription antihistamines for allergic rhinitis and urticaria. The availability of generic versions has intensified competition and influenced pricing strategies.

Key Market Factors:

• Generic Competition: The entry of multiple generic manufacturers has significantly increased the availability of bepotastine besilate tablets and has led to price erosion. This is a common trend for drugs whose patents have expired.
• Branded vs. Generic Pricing: Branded formulations typically command a premium price, while generics offer a more cost-effective alternative. Payers (insurance companies and government health programs) often favor generics due to their lower cost.
• Geographic Market Variations: Market access and prescribing patterns can vary significantly by region, influenced by local regulatory approvals, healthcare systems, and physician preferences.
• Therapeutic Alternatives: Bepotastine besilate competes with a wide range of other oral and topical antihistamines (e.g., cetirizine, loratadine, fexofenadine, olopatadine). The efficacy, side effect profile, and cost of these alternatives influence prescribing decisions.
• Ophthalmic Market Growth: The ophthalmic solution market for allergic conjunctivitis represents a growing segment, with bepotastine besilate ophthalmic solution being a key treatment option.
• Supply Chain Resilience: Global events, geopolitical factors, and disruptions in raw material sourcing can impact the supply chain and create market volatility. Manufacturers with robust and diversified supply chains are better positioned to navigate these challenges.

The competitive landscape for bepotastine besilate is characterized by a mature market for oral tablets due to widespread generic availability, and a more specialized market for ophthalmic solutions. Companies must focus on cost-effective manufacturing, quality assurance, and efficient distribution to remain competitive.

Key Takeaways

• The global supply of bepotastine besilate API is concentrated among specialized manufacturers, primarily in India and potentially other regions with strong chemical synthesis capabilities.
• Key excipients for both tablet and ophthalmic formulations are sourced from established global suppliers adhering to pharmaceutical-grade standards.
• The patent landscape for bepotastine besilate is evolving, with initial compound patents expired and strategic focus shifting to process and formulation patents for generic market entry.
• Strict adherence to GMP, comprehensive regulatory filings (DMFs, ANDAs/MAAs), and robust quality control are mandatory for all stages of bepotastine besilate production and approval.
• The market is characterized by strong generic competition in the oral tablet segment, leading to price pressures, while the ophthalmic solution market presents a growing opportunity.

Frequently Asked Questions

1. What is the typical lead time for procuring bepotastine besilate API from a manufacturer? Lead times can vary widely depending on the manufacturer's production schedule, order volume, and existing contracts, but generally range from 3 to 9 months.

2. Are there any specific impurity concerns that manufacturers of bepotastine besilate API must address? Manufacturers must control specific process-related impurities, degradation products, and residual solvents to meet pharmacopoeial limits (e.g., USP, EP) and regulatory expectations.

3. What is the role of contract manufacturing organizations (CMOs) in the bepotastine besilate supply chain? CMOs play a significant role in both API synthesis and finished dosage form manufacturing, allowing drug developers to leverage specialized facilities and expertise without direct capital investment.

4. How does the regulatory status of a bepotastine besilate API manufacturer in one region (e.g., FDA approval) impact its acceptance in other regions (e.g., EMA)? While FDA approval is a strong indicator of quality, EMA and other regional regulatory bodies may require site inspections or additional documentation to verify compliance with their specific GMP standards.

5. What are the primary differences in the supply chain challenges for bepotastine besilate tablets versus ophthalmic solutions? Ophthalmic solutions require sterile manufacturing environments, specialized preservatives and buffering agents, and stringent controls to prevent microbial contamination, posing unique supply chain and manufacturing complexities compared to oral tablets.

Citations

[1] Kaken Pharmaceutical Co., Ltd. (n.d.). History. Retrieved from [Company Website - example, actual URL would be needed]